IMPAIRED BALANCE OF CLOTTING FACTORS IN LIVER CIRRHOSIS

Authors

  • Anche Volkanovska University Clinic for Gastroenterohepatology, Faculty of Medicine, Skopje, Ss. Cyril and Methodius University, Republic of North Macedonia
  • Violeta Dejanova Institute for Transfusion Medicine, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia
  • Rozalinda Isjanovska Institute of Epidemiology and Biostatistics with Medical Informatics, Faculty of Medicine, Ss. Cyril and Methodius University
  • Emilija Nikolovska Trpchevska University Clinic for Gastroenterohepatology, Faculty of Medicine, Skopje, Ss. Cyril and Methodius University, Republic of North Macedonia
  • Dafina Nikolova University Clinic for Gastroenterohepatology, Faculty of Medicine, Skopje, Ss. Cyril and Methodius University, Republic of North Macedonia
  • Gjorgji Deriban University Clinic for Gastroenterohepatology, Faculty of Medicine, Skopje, Ss. Cyril and Methodius University, Republic of North Macedonia
  • Beti Todorovska University Clinic for Gastroenterohepatology, Faculty of Medicine, Skopje, Ss. Cyril and Methodius University, Republic of North Macedonia
  • Kalina Grivcheva Stardelova University Clinic for Gastroenterohepatology, Faculty of Medicine, Skopje, Ss. Cyril and Methodius University, Republic of North Macedonia
  • Danica Labudovikj Institute of Medical Biochemistry, Faculty of Medicine, Ss. Cyril and Methodius University, Skopje, Republic of North Macedonia

Keywords:

liver cirrhosis hemostasis prothrombotic state

Abstract

Liver cirrhosis (LC) has been accepted as prototype of a disease with acquired prohemorrhagic diathesis. However, as the synthesis of all coagulant factors is affected, a rebalanced but fragile hemostasis is maintained. With increasing disease severity, a disproportion between levels of certain coagulants occurs that can lead to prothrombotic tendency. We aimed to evaluate the levels of factor VIII (FVIII), protein C (PC) and their ratio (FVIII/PC) as the main determinants of thrombin generation in patients with LC at different stages of disease.

Fifty patients with LC were divided in three groups according to LC severity using the Child-Turcotte-Pugh Score (CTP-A, CTP-B, CTP-C). The levels of FVIII and protein C were measured in sodium citrate plasma on Siemens, BCS XP Blood Coagulometer. The levels of FVIII, PC and FVIII/PC were compared between the groups and a correlation of their values to MELD score was performed.

Plasma levels of FVIII increased with severity of the disease, with concurrent statistically significant decrease of plasma PC levels (p=0.0008). This was accompanied with statistically significant increase of the FVIII/PC ratio (p=0.0004) indicating hypercoagulable state in advanced stage of the disease. A significant correlation to MELD score was identified for PC in group CTP-B and CTP-C and for FVIII/PC ratio in group CTP-C. 

As liver cirrhosis severity increases, a disproportion in plasma levels of the most powerful determinants of thrombin generation occurs. This could be the explanation for the observed increased risk of venous thromboembolism in patients with liver cirrhosis.

References

Mann KG. Thrombin formation. Chest 2003; 124(3 Suppl): 4S-10S. doi:10.1378/chest.1 24.3_suppl.4s.

Dahlbäck B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004; 79(2): 109-116. doi: 10.1532/ijh97.03149.

Schiff ER, Sorrell MF, Maddrey WC. Schiff’s disease of the liver. Lippincott Williams & Wilkins, Philadelphia, 2003.

Tripodi A, Primignani M, Chantarangkul V, Dell'Era A, Clerici M, de Franchis R, et al. An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gastroenterology 2009; 137(6): 2105-2111. doi: 10.1053/j.gastro.2009.08.045.

Tripodi A. Hemostasis abnormalities in cirrhosis. Curr Opin Hematol 2015; 22(5): 406-412. doi: 10.1097/MOH.0000000000000164.

Tripodi A, Salerno F, Chantarangkul V, Clerici M, Cazzaniga M, Primignani M, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41(3): 553-558. doi: 10.1002/hep.20569.

Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98 (9): 2730-2735. doi: 10.1182/blood.v98.9.2730.

Noe DA, Murphy PA, Bell WR, Siegel JN. Acute-phase behavior of factor VIII procoagulant and other acute-phase reactants in rabbits. Am J Physiol 1989; 257(1 Pt 2): R49-R56. doi: 10.1152/ajpregu.1989.257.1.R49.

Tripodi A, Anstee QM, Sogaard KK, Primignani M, Valla DC. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost 2011; 9(9): 1713-1723. doi: 10.111 1/j.1538-7836.2011.04429.x.

Søgaard KK , Horváth-Puhó E , Grønbaek H, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol 2009; 104(1): 96-101. doi: 10.1038/ajg.2008.34.

Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45 Suppl 4(Suppl 4): IV1-IV11. doi: 10.113 6/gut.45.2008.iv1.

Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49(3): 1017-1044. doi: 10. 1002/hep.22742.

Tripodi A, Mannucci PM. Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. J Hepatol 2007; 46(4): 727-733. doi: 10.1016/j.jhep.2007.01.015.

Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Bednarz A, Caldwell SH, et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101(7): 1524-1528; quiz 1680. doi: 10.1111/j.1572-0241.2006.00588.x

Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116(6): 878-885. doi: 10.1182/blood-2010-02-261891.

Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. Gut 2005; 54(4): 556-563. doi: 10.1136/gut.2004.048181.

Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124(1): 91-96. doi: 10.1053/gast.2003.50016.

Child CG, Turcotte JG. Surgery and portal hypertension. Major Probl Clin Surg 1964; 1:1-85. PMID: 4950264.

Saxena P, Bihari C, Mirza R, Bhadoria AS, Sarin SK. The imbalance of procoagulant and anticoagulant factors in patients with chronic liver diseases in North India. Blood Res 2017; 52(2): 143-145. doi: 10.5045/br.2017.52.2.143.

Hollestelle MJ, Geertzen HG, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost 2004; 91(2): 267-275. doi: 10.1160/TH03-05-0310.

Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21(5): 731-738. doi: 10.1161/ 01.atv.21.5.731.

Sarin SK, Kedarisetty CK, Abbas Z, Amarapurkar D, Bihari C, Chan AC, et al. APASL ACLF Working Party. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int 2014; 8 (4): 453-471. doi: 10.1007/s12072-014-9580-2.

Agarwal B, Wright G, Gatt A, Riddell A, Vemala V, Mallett S, et al. Evaluation of coagulation abnormalities in acute liver failure. J Hepatol 2012; 57(4): 780-786. doi: 10. 1016/j.jhep.2012.06.020.

Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54(5): 691-697. doi: 10.1136/gut.2004.042796.

Downloads

Published

2023-03-31

Issue

Vol. 3 No. 1 (2023): Acad Med J

Section

Original Articles